Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Replimune Group, Inc.

Replimune is developing a novel class of oncolytic immunotherapies aimed at treating difficult-to-treat cancers by igniting a patient-specific immune response. These therapies are designed to be tolerable and effective in the local killing of tumors.

COM:REPLIMUNE

Replimune

Last Close

11.05

22/11 21:00

Market Cap

961.18M

Beta: -

Volume Today

6.07M

Avg: -